This article is more than 5 years old. Information may no longer be current.

Lower-dose Alphagan P launched

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — A lower-dose version of a common glaucoma drug is now available, according to an Allergan press release.

Allergan is now marketing Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% to lower IOP in patients with open-angle glaucoma or ocular hypertension. Alphagan P 0.1% is the “lowest effective dose of brimonidine,” Allergan said in the release.

“Results from a 12-month clinical trial show that IOP reductions with new Alphagan P 0.1% ophthalmic solution were clinically equivalent to the original Alphagan 0.2%,” Allergan said. There was less than a 1-mm-Hg difference between the two dosing levels in patients who were followed over 12 months.